Monoclonal antibodies in chronic lymphocytic leukemia

Alessandra Ferrajoli, Stefan Faderl, Michael J. Keating

Research output: Contribution to journalReview articlepeer-review

4 Scopus citations

Abstract

Multiple options are now available for the treatment of chronic lymphocytic leukemia. Over the last 10 years, monoclonal antibodies have become an integral part of the management of this disease. Alemtuzumab has received approval for use in patients with fludarabine-refractory chronic lymphocytic leukemia. Rituximab has been investigated extensively in chronic lymphocytic leukemia both as a single agent and in combination with chemotherapy and other monoclonal antibodies. Epratuzumab and lumiliximab are newer monoclonal antibodies in the early phase of clinical development. This article will review the monoclonal antibodies more commonly used to treat chronic lymphocytic leukemia, the results obtained with monoclonal antibodies as single agents and in combination with chemotherapy, and other biological agents and newer compounds undergoing clinical trials.

Original languageEnglish (US)
Pages (from-to)1231-1238
Number of pages8
JournalExpert review of anticancer therapy
Volume6
Issue number9
DOIs
StatePublished - Sep 2006

Keywords

  • Chemoimmunotherapy
  • Chronic lymphocytic leukemia
  • Monoclonal antibodies
  • Treatment

ASJC Scopus subject areas

  • Oncology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Monoclonal antibodies in chronic lymphocytic leukemia'. Together they form a unique fingerprint.

Cite this